Ankündigung • Jun 12
Poongjeon Pharmacy CO.,LTD. announced that it expects to receive KRW 3.99999812 billion in funding from Korea Investment & Securities Co., Ltd. and another investor.. Poongjeon Pharmacy CO., LTD announced a private placement to issue 796,812 common shares at an issue price of KRW 2510 per share for gross proceeds of KRW 1,999,998,120 on June 10, 2026. The transaction includes participation from new investor Cony New Technology Association No. 63. The transaction has been approved by shareholders, expected to close on June 30, 2026. The payment date of is June 30, 2026. Private placement issuance is subject to mandatory lockup for 1 year.
On the same date the company announced a private placement to issue series 3 unsecured convertible bonds for gross proceeds of KRW 2,000,000,000. The transaction will include participation from new investor, Korea Investment & Securities Co., Ltd. The bonds will carry an interest rate of 2% and will have a maturity interest rate of 2%. The bonds will mature on June 18, 2029. The bonds will be 100% convertible into 600,240 common shares of the company at a conversion price of KRW 3,332. The conversion period for the bonds will be between June 18, 2027 to May 18, 2029. The transaction has been approved by the board of directors of the company and is expected to close on June 18, 2026. The securities issued in the transaction will be held for a lockup period of 1 year. The payment date is June 18, 2026. New Risk • Jun 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (₩1.5b revenue, or US$1.0m). Market cap is less than US$100m (₩26.5b market cap, or US$17.4m). New Risk • Jun 06
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: ₩1.5b (US$989k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Revenue is less than US$1m (₩1.5b revenue, or US$989k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (₩23.6b market cap, or US$15.2m). Board Change • May 19
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). CEO & Chairman Byeong-gwan Son was the last director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Ankündigung • Mar 10
SCM Lifescience Co., Ltd., Annual General Meeting, Mar 24, 2026 SCM Lifescience Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 7-7, gaetbeol-ro 145beon-gil, yeonsu-gu, incheon South Korea New Risk • Feb 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (₩1.5b revenue, or US$1.1m). Market cap is less than US$100m (₩37.3b market cap, or US$25.9m). Ankündigung • Sep 16
SCM Lifescience Co., Ltd. announced that it has received KRW 4 billion in funding On September 15, 2025, SCM Lifescience Co., Ltd. closed the transaction. Ankündigung • Sep 08
SCM Lifescience Co., Ltd. announced that it expects to receive KRW 6.999999488 billion in funding SCM Lifescience Co., Ltd announced a private placement to issue series 2 bearer unsecured convertible bonds for gross proceeds of KRW 2,000,000,000 on September 8, 2025. The transaction will include participation from new investor, Koni New Technology Fund No. 63. The bonds will carry an interest rate of 2% and will have a maturity interest rate of 2%. The bonds will mature on October 2, 2028. The bonds will be 100% convertible into 1,692,047 common shares of the company at a conversion price of KRW 1,182. The conversion period for the bonds will be between October 2, 2026 to September 2, 2028. The transaction has been approved by the board of directors of the company and is expected to close on October 2, 2025. The securities issued in the transaction will be held for a lockup period of 1 year.
On the same date, the company will also issue 4,734,848 common shares at an issue price of KRW 1,056 for gross proceeds of KRW 4,999,999,488. The transaction includes participation from new investor, Aria New Technology Fund No. 95. The transaction has been approved by the board of directors of the company and is expected to close on October 2, 2025. The securities issued in the transaction will be held for a lockup period of 1 year. New Risk • Aug 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩17b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩1.5b revenue, or US$1.1m). Market cap is less than US$100m (₩39.5b market cap, or US$28.5m). Ankündigung • Jul 03
SCM Lifescience Co., Ltd. (KOSDAQ:A298060) completed the acquisition of poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330). SCM Lifescience Co., Ltd. (KOSDAQ:A298060) agreed to acquire poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) for KRW 8.2 billion on June 17, 2025. A cash consideration of KRW 8.21 billion will be paid by SCM Lifescience Co., Ltd. As part of consideration, KRW 8.21 billion is paid towards common equity of poong jun pharmaceutica wholesale co., ltd. The transaction will be financed through equity investment of KRW 8.21 billion.
For the period ending December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total revenue of KRW 37.02 billion and net income of KRW 630 million. As of December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total debt of KRW 7.95 billion and total assets of KRW 17.37 billion.
The expected completion of the transaction is July 1, 2025.
SCM Lifescience Co., Ltd. (KOSDAQ:A298060) completed the acquisition of poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) on July 1, 2025. Kumho HT, Inc. has received the balance of payment for the shares. Ankündigung • Jun 27
SCM Lifescience Co., Ltd. announced that it has received KRW 2.999999525 billion in funding On June 25, 2025. SCM Lifescience Co., Ltd. has closed the transaction. Ankündigung • Jun 18
SCM Lifescience Co., Ltd. (KOSDAQ:A298060) agreed to acquire poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) for KRW 8.2 billion. SCM Lifescience Co., Ltd. (KOSDAQ:A298060) agreed to acquire poong jun pharmaceutica wholesale co., ltd from Kumho HT, Inc. (KOSE:A214330) for KRW 8.2 billion on June 17, 2025. A cash consideration of KRW 8.21 billion will be paid by SCM Lifescience Co., Ltd. As part of consideration, KRW 8.21 billion is paid towards common equity of poong jun pharmaceutica wholesale co., ltd. The transaction will be financed through equity investment of KRW 8.21 billion. For the period ending December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total revenue of KRW 37.02 billion and net income of KRW 630 million. As of December 31, 2024, poong jun pharmaceutica wholesale co., ltd reported total debt of KRW 7.95 billion and total assets of KRW 17.37 billion.
The expected completion of the transaction is July 1, 2025. Ankündigung • Jun 12
SCM Lifescience Co., Ltd. announced that it expects to receive KRW 7.99999923 billion in funding SCM Lifescience Co., Ltd announced a private placement to issue 10,738,254 common shares at an issue price of KRW 745 per share for gross proceeds of KRW 7,999,999,230 June 10, 2025. The transaction will include participation from new investor Marcia New Technology Fund No. 77 The transaction has been approved by shareholders, expected to close on June 25, 2025.
4,026,845 - The transaction will issue 4,026,845 shares at an issue price of KRW 745 per share for gross proceeds of KRW 2,999,999,525. The transaction will include participation from new investor Marcia New Technology Fund No. 77 The transaction has been approved by shareholders, expected to close on June 25, 2025.
6,711,409 - The transaction will issue 6,711,409 shares at an issue price of KRW 745 per share for gross proceeds of KRW 4,999,999,705.The transaction will include participation from new investor Marcia New Technology Fund No. 77 The transaction has been approved by shareholders, expected to close on July 25, 2025. New Risk • Apr 15
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 36% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (36% increase in shares outstanding). Revenue is less than US$1m (₩825m revenue, or US$578k). Minor Risk Market cap is less than US$100m (₩28.5b market cap, or US$20.0m). Ankündigung • Apr 15
SCM Lifescience Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.99999 million. SCM Lifescience Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.99999 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 990,099
Price\Range: KRW 1010
Transaction Features: Subsequent Direct Listing Ankündigung • Mar 26
SCM Lifescience Co., Ltd. announced that it has received KRW 7.9999997 billion in funding On March 24, 2025, SCM Lifescience Co., Ltd., closed the transaction. New Risk • Mar 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m (₩889m revenue, or US$608k). Minor Risk Market cap is less than US$100m (₩27.3b market cap, or US$18.7m). Ankündigung • Mar 18
SCM Lifescience Co., Ltd., Annual General Meeting, Mar 31, 2025 SCM Lifescience Co., Ltd., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 7-7, gaetbeol-ro 145beon-gil, yeonsu-gu, incheon South Korea New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (₩40.9b market cap, or US$28.5m). Reported Earnings • Nov 02
Third quarter 2024 earnings released: ₩150 loss per share (vs ₩393 loss in 3Q 2023) Third quarter 2024 results: ₩150 loss per share (improved from ₩393 loss in 3Q 2023). Net loss: ₩3.07b (loss narrowed 50% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Reported Earnings • May 18
First quarter 2024 earnings released: ₩157 loss per share (vs ₩461 loss in 1Q 2023) First quarter 2024 results: ₩157 loss per share (improved from ₩461 loss in 1Q 2023). Net loss: ₩3.21b (loss narrowed 43% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings. New Risk • Mar 27
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩12b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩12b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m (₩696m revenue, or US$516k). Minor Risks Shareholders have been diluted in the past year (41% increase in shares outstanding). Market cap is less than US$100m (₩61.6b market cap, or US$45.7m). New Risk • Nov 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 41% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 24% over the past year. Revenue is less than US$1m (₩352m revenue, or US$267k). Minor Risks Shareholders have been diluted in the past year (41% increase in shares outstanding). Market cap is less than US$100m (₩59.9b market cap, or US$45.5m). New Risk • Nov 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩11b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 24% over the past year. Revenue is less than US$1m (₩352m revenue, or US$267k). Minor Risk Market cap is less than US$100m (₩37.8b market cap, or US$28.7m). Ankündigung • Sep 08
SCM Lifescience Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 18.36 billion. SCM Lifescience Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 18.36 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 4,800,000
Price\Range: KRW 3825
Discount Per Security: KRW 79.2
Transaction Features: Rights Offering New Risk • Jul 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩12b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 16% over the past year. Revenue is less than US$1m (₩380m revenue, or US$298k). Minor Risk Market cap is less than US$100m (₩75.6b market cap, or US$59.3m). Is New 90 Day High Low • Feb 24
New 90-day low: ₩33,550 The company is down 4.0% from its price of ₩35,050 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period. Is New 90 Day High Low • Jan 04
New 90-day high: ₩55,400 The company is up 85% from its price of ₩30,000 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period. Is New 90 Day High Low • Dec 03
New 90-day high: ₩37,000 The company is up 10.0% from its price of ₩33,750 on 04 September 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 2.0% over the same period. 